ALGN
Get informed when a big investor buys or sells
+ FollowOvervalued by 38.4% based on the discounted cash flow analysis.
| Market cap | $12.53 Billion |
|---|---|
| Enterprise Value | $12.86 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $5.66 |
| Beta | 1.7 |
| Outstanding Shares | 71,425,000 |
| P/E Ratio | 29.07 |
|---|---|
| PEG | 138.68 |
| Price to Sales | 2.84 |
| Price to Book Ratio | 2.79 |
| Enterprise Value to Revenue | 3.14 |
| Enterprise Value to EBIT | 21.89 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.33 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2111▲ 27.67% |
|---|---|
| Total Calls | 815,901▼ 35.64% |
| Total Puts | 988,128▼ 16.58% |
Holdings and activity of institutional investors.
| Ownership % | 95.38%▲ 3.98% |
|---|---|
| Total Invested | $11.85B▲ 14.42% |
| Investors Holding | 726▲ 18.00% |
No data
This committee provides the official analysis and 'scoring' for all tax legislation, directly influencing corporate tax structures and capital investment credits. Its technical expertise and reports directly shape the fiscal environment for companies like Align Technology.
This is a powerful committee controlling taxation, trade, and entitlement spending. Its decisions on corporate tax rates, tariffs on imported components, or healthcare entitlement policies (which can influence overall healthcare pricing) directly impact Align Technology's profitability and cost of goods.
This committee has direct oversight of the FDA, which regulates medical devices. Its decisions on device approvals, safety standards, and labeling requirements are paramount to Align Technology's ability to develop, market, and sell its products.
This committee directly oversees antitrust laws and intellectual property. For a medical device company like Align Technology, protecting patents and trade secrets is critical, and antitrust scrutiny could impact its market strategy or M&A activities.